2023 Prepped and Primed: Prescient Therapeutics (ASX:PTX) with CEO and managing director, Steven Yatomi-Clarke
Stockhead’s Prepped and Primed video series is a yearly wrap up address from company leaders...
Stockhead’s Prepped and Primed video series is a yearly wrap up address from company leaders...
Prescient Therapeutics Ltd (ASX:PTX) CEO and managing director Steven Yatomi-Clarke chats with Andrew Scott from Proactive about the...
Prescient’s PTX-100 Phase 1b study shows encouraging responses on a patient population that is notoriously...
“It is very exciting to see PTX-100 show clinical activity in a patient population that...
A study by Prescient Therapeutics (ASX: PTX) into the effects of lead drug PTX-100 on relapsed and...
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke presented at the...
Prescient Therapeutics CellPryme-A Briefing Prescient Therapeutics CEO and MD Steven Yatomi-Clarke and Senior VP of...
Prescient Therapeutics Investor Briefing Prescient Therapeutics CEO and MD Steven Yatomi-Clarke and Senior VP of...
ASX-listed biotech Prescient Therapeutics is crossing a major inflection point on the back of three...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.